Quercetin for COPD

Phase 1 & 2

Recruiting

Led By Nathaniel Marchetti, D.O.

Research Sponsored by Temple University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Both active and ex-smokers with at least 10 pack-years history of smoking

COPD patients taking H2 antagonists, loperamide or loratadine and willing to stop during the study period

Timeline

Screening 3 weeks

Treatment Varies

Follow Up six months

Awards & highlights

Study Summary

This trial tests if quercetin can reduce inflammation and oxidative stress in COPD patients. 8 take quercetin, 4 take placebo.

Who is the study for?

This trial is for COPD patients aged 40-80, who are current or former smokers with a significant smoking history. They must have specific lung function test results and be willing to stop certain medications during the study. It's not for those allergic to quercetin, with asthma, recent infections or hospitalizations, high dietary quercetin intake, on warfarin/cyclosporine, with lung cancer treatments or inflammatory bowel disease.Check my eligibility

What is being tested?

The trial tests if taking quercetin (2000 mg/day) can reduce inflammation and oxidative stress in COPD patients compared to a placebo group. The small study involves 8 subjects on quercetin and 4 on placebo to see the biological effects of this supplement.See study design

What are the potential side effects?

While not explicitly listed in the provided information, common side effects of quercetin may include headaches, tingling sensations, and mild stomach discomfort. Since it's being tested for its anti-inflammatory properties in COPD patients here, monitoring will likely focus on any respiratory symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have smoked at least 10 packs of cigarettes a year.

Select...

I have COPD and am willing to stop taking H2 antagonists, loperamide, or loratadine for the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ six months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~six months

This trial's timeline: 3 weeks for screening, Varies for treatment, and six months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Inflammatory markers

Oxidative stress markers

Secondary outcome measures

Quercetin

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: QuercetinActive Control1 Intervention

Quercetin 2000 mg/day Quercetin is provided as orange flavored soft chews and each chew will have 250 mg of quercetin Quercetin will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.

Group II: PlaceboPlacebo Group1 Intervention

Placebo is also provided as soft chews that is similar to quercetin in color, taste and texture and will contain all the stabilizers and the inactive ingredients that is present in the quercetin chews. Placebo will be administered orally twice daily, one half dose (4 chews) in the morning after breakfast and one half dose (4 chews) in the evening after dinner for six months.

0 / 2Eligibility criteria met